logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2019
Conatus Pharmaceuticals Inc
Data from Phase 2b clinical trial of Emricasan (ENCORE-LF)
decompensated NASH cirrhosis
2H 2019
Endocyte, Inc.
1st interim assessment of overall survival in phase III trial of 177Lu-PSMA-617
Metastatic castration-resistant prostate cancer
Q3 2019
The Medicines Co.
Data read-out from 1st Phase III pivotal clinical trial of inclisiran (ORION-10)
LDL-cholesterol with atherosclerotic cardiovascular disease
Q3 2019
The Medicines Co.
Data read-out from 2nd pivotal Phase III LDL-C lowering trial of inclisiran(ORION-9)
LDL-cholesterol with atherosclerotic cardiovascular disease
Q3 2019
The Medicines Co.
Data read-out from 3rd pivotal Phase III LDL-C lowering trial of inclisiran(ORION-11)
LDL-cholesterol with atherosclerotic cardiovascular disease
Q3 2019
Myovant Sciences Ltd
Data from 2nd phase III trial of Relugolix (LIBERTY 2)
Heavy menstrual bleeding associated with uterine fibroids in Women
2H 2019
KalVista Pharmaceuticals, Inc.
Data from Phase 2 clinical trial of KVD001
Diabetic macular edema
2H 2019
SOLIGENIX, INC.
Final results from phase III study of SGX942 (dusquetide)
Oral mucositis in patients with head and neck cancer
2H 2019
Allena Pharmaceuticals, Inc.
Topline data from phase III trial of ALLN-177 (URIROX-1)
Enteric Hyperoxaluria
2H 2019
Celsion Corp.
Data from 1st interim efficacy results from phase III study of ThermoDox (OPTIMA)
primary liver cancer
Q3 2019
Zynerba Pharmaceuticals, Inc.
Top line results from phase II study of ZYN002 (BELIEVE 1 study)
Developmental And Epileptic Encephalopathies (DEE)
Q3 2019
Heat Biologics Inc.
Interim data from Phase 1 clinical trial of PTX-35
Non Small Cell Lung Cancer (NSCLC)
2H 2019
Retrophin Inc.
Top-line data from phase III trial of Fosmetpantotenate (FORT)
Pantothenate kinase-associated neurodegeneration
2H 2019
BioXcel Therapeutics, Inc.
Final proof of concept readout from phase II trials of BXCL701
Rare form of prostate cancer and for treatment of pancreatic cancer
2H 2019
ObsEva SA
24-week primary endpoint data from two phase III trials of OBE2109 (PRIMROSE 1 and 2)
Uterine fibroids
2H 2019
Catalyst Pharmaceutical Partners Inc.
Top-line results from phase III trial of Firdapse
Congenital myasthenic syndromes
2H 2019
BeyondSpring Inc.
Submission of NDA for Plinabulin
Chemotherapy-induced neutropenia (CIN)
2H 2019
Daré Bioscience, Inc
Data from post-coital test (PCT) clinical trial of Ovaprene
Non-Hormonal Monthly Contraceptive Candidate
2H 2019
Nightstar Therapeutics plc
One-year follow-up data from dose escalation cohorts of Phase 1/2 Gene Therapy (NSR-RPGR) clinical trial
X-Linked Retinitis Pigmentosa (XLRP)
Q3 2019
RHYTHM PHARMACEUTICALS, INC.
Initial data from phase III trial of Setmelanotide
pro-opiomelanocortin (POMC) Obesity
Q3 2019
RHYTHM PHARMACEUTICALS, INC.
Initial data from phase III trial of Setmelanotide
leptin receptor (LEPR) Obesity
2H 2019
Iterum Therapeutics plc
Top-line results from first phase III clinical trial of Oral Sulopenem (SURE)
Uncomplicated urinary tract infections (uUTI)
2H 2019
Zynerba Pharmaceuticals, Inc.
Topline results from pivotal trial of ZYN002 (CONNECT-FX)
Fragile X Syndrome
2H 2019
MyoKardia Inc
Data from phase II study of Mavacamten (MAVERICK-HCM)
Hypertrophic Cardiomyopathy
2H 2019
Solid Biosciences Inc.
Initial data from pre-specified interim analysis of Phase I/II Clinical Trial of SGT-001 ( IGNITE DMD)
Duchenne muscular dystrophy (DMD)